Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma, celebrated the opening of its expanded antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland, UK.

This expansion further enhances the site's capacity by approximately seventy to eighty percent, enabling scale-up of commercial ADC manufacturing batches. The capacity expansion, which has been completed for commercialisation within this fiscal year, features two new ADC manufacturing suites specifically designed to complement the existing three. The commissioning of the facility represents the culmination of a £45 million investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4 million Scottish Enterprise grant.

The site expansion includes a dedicated customer experience centre for clients who are visiting the site during development and/or manufacturing activities, along with new Quality Control laboratories, warehousing, office space, and supporting utilities.

The building, which utilised modular construction technology to expedite its completion, has been designed to accommodate further expansion. Potential future enhancements may include a new sterile fill/finish suite dedicated to ADCs and two additional large-scale manufacturing suites capable of handling increased batch sizes.